VolitionRx (VNRX) said Friday its automated Nu.Q Cancer immunoassay test in development detected 21 different types of cancer in a recent study.

The study included 229 cancer patients and 150 healthy participants and demonstrated that the test detected common fatal cancers, including lung, breast, prostate, colon and liver, with a very low rate of false positives, Volition RX said.

This technology could function as a standalone pan-cancer test or be licensed for use with other liquid biopsy tools, largely due to its low false positive rate in healthy individuals, the company said.

VolitionRX said it is in discussions with multiple major diagnostic and liquid biopsy firms to secure licensing deals this year that include milestone-based payments and ongoing revenue.